Latest Regulatory Pathways News

Akora Resources has completed a $3.3 million equity raise combining a $1.6 million placement and a modest $187,000 entitlement offer, positioning the company to push forward with mine development following its recent mining permit grant.

The Calmer Co. has won Coles' approval for its innovative Fiji Kava® FZZR™ product, extending its Australian supermarket reach while gearing up for a broader U.S. retail rollout supported by a key brokerage partnership.

Western Australia's State Government has backed VRX Silica's land swap proposal at Muchea, unlocking access to a significantly larger high-grade silica sand resource with lower environmental impact and paving the way for downstream glass manufacturing.

CONNEQT Health has lodged an FDA Pre-Submission for SphygmoCor Cloud, aiming to shift its arterial health analytics from hardware to a scalable software platform with broad commercial potential.

Jindalee Lithium’s US subsidiary, HiTech Minerals, has partnered with environmental nonprofit RESOLVE to investigate a voluntary stewardship area around its McDermitt Lithium Project, aiming to balance responsible lithium development with conservation efforts.

Island Pharmaceuticals has presented encouraging Phase 2a results for its dengue antiviral ISLA-101, demonstrating safety, effective blood concentrations, and meaningful viral load reductions at the Asia Dengue Summit.

CLINUVEL Pharmaceuticals has lodged its Form 20-F with the U.S. SEC, seeking to elevate its American Depository Receipt program to a Nasdaq-listed American Depository Share, aiming to boost visibility and liquidity without raising capital.

Encounter Resources is aggressively advancing its Aileron niobium project in Western Australia with a comprehensive 70,000-metre drilling campaign and a Mining Lease application, underpinning its push toward development.

Island Pharmaceuticals is accelerating development of its broad-spectrum antiviral Galidesivir, progressing clinical, regulatory, and manufacturing milestones under the FDA Animal Rule pathway with expanded USAMRIID collaboration and biodefence positioning.

Island Pharmaceuticals has expanded its partnership with USAMRIID to conduct a pivotal Galidesivir dose optimisation study against Marburg virus, targeting topline results in the second half of 2026.

Island Pharmaceuticals has kicked off GMP manufacturing of its antiviral Galidesivir to support late-stage Marburg virus studies under the FDA Animal Rule, marking a key step towards regulatory submission and biodefence readiness.

DPM Metals has revealed a major new gold-copper porphyry discovery at its Brevene South Porphyry target adjacent to the Chelopech mine, with drill results showing broad intervals of high-grade mineralization and plans for an intensive follow-up drilling campaign.